Itraconazole in the treatment of tinea pedis and tinea manuum: Comparison of two treatment schedules

Mycoses

Volumn 41, Issue 11-12, 1998, Pages 515-520

  Schuller, J ^a   Remme, J J ^b   Rampen, F H J ^c   Van Neer, F C J ^d  

^a Drechtsteden Ziekenhuis   (Netherlands)

^b Infection and Immunology   (Netherlands)

^c ST ANNA HOSPITAL   (Netherlands)

^d Sittard Geleen Heerlen   (Netherlands)

Author keywords

Antimycotic chemotherapy; Dermatophytosis; Itraconazole; Tinea manuum; Tinea pedis

Indexed keywords

ANTIFUNGAL AGENT; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOMYCOSIS; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE AND FACIAL PAIN; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TINEA; TINEA MANUUM; TINEA PEDIS;

TINEA;

EID: 0032436451     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.1998.tb00715.x     Document Type: Article

References (12)

1. Martin, A. G. & Kobayashi, G. S. (1993) Fungal diseases with cutaneous involvement. In: Fitzpatrick, T. B., Eisen, A. Z., Wolff, K., Freedberg, I. M. & Austen, K. F., eds. Dermatology in General Medicine, 4th edn. New York: McGraw-Hill, pp. 2421-2451.
2. Elewski, B. & Hay, R. J. (1995) International summit on cutaneous antifungal therapy. J. Am. Acad. Dermatol. 33, 816-822.
3. Heiberg, J. K. & Svejgaard, E. (1981) Toxic hepatitis during ketoconazole treatment. BMJ 283, 825.
4. Cauwenbergh, G. (1989) Safety aspects of ketoconazole, the most commonly used systemic antifungal. mycoses 32 (Suppl. 2), 59-63.
5. De Doncker, P. & Cauwenbergh, G. (1990) Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review. Br. J. Clin. Pact. 44, 118-122.
6. Van Cutsem, J., Van Gerven, F. & Janssen, P. A. J. (1987) Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev. Infect. Dis. 9 (Suppl. 1), S15-S32.
7. Van Cutsem, J. (1989) The in-vitro antifungal spectrum of itraconazole. mycoses 32 (Suppl. 1), 7-13.
8. De Beule, K., Lubin, G. & Cauwenbergh, G. (1991) Safety aspects of itraconazole therapy in vaginal candidosis, dermatoniycosis and onychomycosis: a review. Curr. Ther. Res. 49, 814-822.
9. Cauwenbergh, G., Degreef, H., Heykants, J., Woestenborghs, R., Van Rooy, P. & Haeverans, K. (1988) Pharmacokinetic profile of orally administered itraconazole in human skin. J. Am. Acad. Dermatol. 18, 263-268.
10. Piérard, G. E., Arrese, J. E. & De Doncker, P. (1995) Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J. Am. Acad. Dermatol. 32, 429-435.
11. Decroix, J. (1995) Tinea pedis (moccasin-type) treated with itraconazole. Int J. Dematol. 34, 122-124.
12. Gupta, A. K., De Doncker, P., Heremans, A. et al. (1997) Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 4 weeks. J. Am. Acad. Dermatol. 36, 789-792.